A phase I study of a HER2/neu bispecific antibody with granulocyte- colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu

Cancer Immunology Immunotherapy

Volumn 48, Issue 1, 1999, Pages 9-21

  Pullarkat, V ^a   Deo, Y ^b   Link, J ^a   Spears, L ^a   Marty, V ^a   Curnow, R ^a   Groshen, S ^a   Gee, C ^a   Weber, J S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEDAREX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; MDX H 210; NEU DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC REACTION; ANTIBODY TITER; ARTICLE; BREAST CANCER; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DIARRHEA; DOSE CALCULATION; DRUG EFFECT; DRUG HALF LIFE; DRUG SCREENING; DRUG TOLERABILITY; FEVER; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ANTIBODIES, BISPECIFIC; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-6; MICE; MIDDLE AGED; RECEPTOR, ERBB-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032919486     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050543     Document Type: Article

References (36)

1. 1. Beun GDM, Gorter A, Nooyen Y, et al (1993) T cell retargeting using bispecific monoclonal antibodies in a rat colon adenocarcinoma model. II. Syngeneic colon carcinoma CC531 is efficiently killed by retargeted cytotoxic T lymphocytes in vitro despite limited lysis in chromium release assays. J Immunol 150:2305
2. 2. Clark M, Bolt S, Tunnacliffe A, Waldman H (1991) In: Romet-Lemonne, Fanger MW, Segal Bispecific antibodies and targeted cellular cytotoxicity. p 243
3. 3. Cohen AM, Zsebo KM, Inoue H, et al (1987) In vivo stimulation of granulopoesis by recombinant human granulocyte colony stimulating factor. Proc Natl Acad Sci USA 84:2484
4. 4. Crawford J, Ozer H, Stoller R, et al (1991) Reduction by granulocyte colony stimulating factor of the fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164
5. 5. Ely P, Wallace PK, Givan AL, et al (1996) Bispecific-armed, Interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkinís lymphoma. Blood 87:3813
6. 6. Fanger MW, Guyre PM (1991) The use of bispecific antibodies. Trends Biotechnol 9:375
7. 7. Fanger MW, Shen L, Graziano RF et al (1989) Cytotoxicity mediated by human Fc receptors for IgI. Immunol Today 10:92
8. 8. Fanger MW, Morganelli PM, Guyre PM (1992) Bispecific antibodies. Crit Rev Immunol 12:101
9. 9. Gabrilove JL, Jakubowsi A, Scher H, et al (1988) Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1412
10. 10. Graziano RF, Tempest PR, White P, et al (1995) Construction and characterization of a humanized anti-gamma Ig receptor Type I monoclonal antibody. J Immunol 155:4996
11. 11. Gusterson BA, Geller RD, Goldhirsch A, et al (1992) Prognostic implication of c-erbB2 expression on breast cancer: a 30 year follow-up. J Clin Oncol 10:1049
12. 12. Guyre PM, Graziano RF, Vance BA, et al (1989) Monoclonal antibodies that bind to distinct epitopes on FcgR1 are able to trigger effector function. J Immunol 143:1650
13. 13. Hartmann F, Renner C, Jung W, et al (1997) Treatment of refractory Hodgkin's disease with an anti-CD 16/CD30 bispecific antibody. Blood 89:2042
14. 14. James N, Atherton P, Koletsky A, et al (1998) Phase II trial of the bispecific antibody MDX-H210 (anti HER2/neu X anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinoma that express HER2/neu (abstract). Proc Am Soc Clin Oncol 17:436a
15. 15. Kaufman PA, Memoli V, Wells W, et al (1995) Increased incidence of HER-2/neu overexpression in metastatic breast and ovarian carcinoma (abstract) Proc Annu Meet Am Soc Clin Oncol 14:A1371
16. 16. Keller T, Graziano RF, Mandal A, et al (1997) Bispecific antibody-dependent cellular cytotoxicity of HER-2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Cancer Res 57:4008
17. 17. Looney RJ, Abraham GN, Anderson CL (1986) Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136:1641
18. 18. Lopez AF, Nicola AN, Burgess AW, et al (1983) Activation of granulocyte cytotoxic function by purified mouse colony stimulating factors. J Immunol 131:2983
19. 19. Matsumoto Y, Saiki I, Murata J, et al (1991) Recombinant human granulocyte colony stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice. Int J Cancer 49:444
20. 20. Ojik HH van, Repp R, Groenewegen G, et al (1997) Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RIX anti-HER2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer. Cancer Immunol Immunother 45:207
21. 21. Parren PWHI, Warmerdam PAM, Boeiji LCM, et al (1992) On the interaction of IgG subclasses with the low affinity FcgRIIa (CD32) receptor on human monocytes, neutrophils, and platelets: analysis of a functional polymorphism to human IgG2. J Clin Invest 90:1537
22. 22. Perussia B, Dayton ET, Lazarus R, et al (1983) Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med 158:1012
23. 23. Press M, Pike M, Chazin V, et al (1993) HER-2/neu expression in node-negative breast cancers: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960
24. 24. Press M, Hung G, Godolphin W, et al (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of expression. Cancer Res 54:2771
25. 25. Ravetch JV, Kinet JP (1991) Fc receptors. Annu Rev Immunol 9:457
26. 26. Repp R, Valerius T, Sendler A, et al (1991) Neutrophils express the high affinity receptor for IgG (FcgR1; CD 64) after in vivo application of rh G-CSF. Blood 78:885
27. 27. Repp R, Valerius T, Wieland G, et al (1995) G-CSF stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER2/neu (MDX-210). J Hematother 4:415
28. 28. Shen L, Guyre PM, Anderson CL, Fanger MW (1986) Hetero-antibody mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by gamma-interferon and is not blocked by human IgG. J Immunol 137:3378
29. 29. Slamon DJ, Clark GM, Wong SG, et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177
30. 30. Slamon DJ, Godolphin W, Jones LA, et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707
31. 31. Stockmeyer B, Valerius T, Repp R, et al (1997) Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER2/neu overexpressing breast cancer. Cancer Res 57:696
32. 32. Toikkanen S, Helin H, Isola J, et al (1992) Prognostic significance of HER2/neu oncoprotein expression in breast cancer: a 30 year follow-up. J Clin Oncol 10:1044
33. 33. Valerius T, Repp R, Wit TPM de, et al (1993) Involvement of the high affinity receptor for IgG (FcgRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82:931
34. 34. Valone FH, Kaufman PA, Guyre PM, et al (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281
35. 35. Van de Winkel JGJ, Anderson CL (1991) Biology of human immunoglobulin G Fc receptors. J Leucoc Biol 49:511
36. 36. Weiner LM, Clark JI, Davey M, et al (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erb B2 and Fc gamma R III. Cancer Res 55:4586